Osteosarcoma · 11 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Regorafenib monotherapy Variant #06 | — | R 307 423 | 28d | 3.6 mo | — | 4 | R 1 229 690 PFS proxy | 1 |
Cabozantinib monotherapy Variant #01 | — | R 90 983 | 28d | ~9.3 mo | ~16.2 mo | ~11 | ~R 1 000 811 PFS proxy · indirect | 17 |
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | — | — | — | — | 1 |
Gemcitabine monotherapy Variant #20 | — | R 14 213 | 56d | ~4.0 mo | ~7.5 mo | ~3 | ~R 42 639 PFS proxy · indirect | 66 |
ICE Variant #01 | — | R 11 539 | 14d | — | ~13.9 mo | — | — | — |
Cyclophosphamide and Topotecan Variant #01 | — | R 6 079 | 21d | — | — | — | — | — |
IE N/A - secondary systemic drug | — | R 5 678 | 28d | — | — | — | — | — |
Docetaxel and Gemcitabine Variant #01 | — | R 4 912 | 21d | ~6.2 mo | — | ~9 | ~R 44 207 PFS proxy · indirect | 1 |
Cyclophosphamide and Etoposide Variant #01 | — | R 3 045 | 28d | — | — | — | — | — |
Placebo Partial | — | — | — | 1.7 mo | — | — | — | 1 |
Samarium-153 with stem cell support Variant #01 Partial | — | — | — | — | — | — | — | — |
11 of 11 regimens shown